zasocitinib

Sponsor Takeda Pharmaceutical CO LTD · listed as TAK

READOUT Phase 3 Confidence: medium Source: clinicaltrials

zasocitinib is a clinical-stage drug asset sponsored by Takeda Pharmaceutical CO LTD, listed as TAK. CSA tracks 1 forward catalyst for it — the nearest is a readout expected May 18, 2027 (day precision, medium confidence), tied to trial NCT06671483. The asset is in Phase 3 and currently recruiting, studied in Psoriatic Arthritis. It appears across 6 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-05-18

As disclosedMay 18, 2027

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT06671483

PhasePHASE3

StatusRECRUITING

Lead sponsorTakeda

Listed asTAK

Condition(s)Psoriatic Arthritis

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More TAK catalysts